<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527772</url>
  </required_header>
  <id_info>
    <org_study_id>LD-FOX4/HCC</org_study_id>
    <nct_id>NCT02527772</nct_id>
  </id_info>
  <brief_title>Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma</brief_title>
  <acronym>LD-FOX4/HCC</acronym>
  <official_title>Liposomal Doxorubicin(LD) Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangxi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine that Liposomal Doxorubicin(LD) plus
      Gemcitabine(GEM) is superior to Oxaliplatin（OXA） Plus Fluorouracil/Leucovorin(FOLFOX4) in
      prolonging progression-free survival（PFS） in patients with Advanced Hepatocellular Carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free-Survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-Progression</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Liposomal Doxorubicin+Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine 1000mg/m2,d1,8;Liposomal Doxorubicin 30mg/m2,d1.q4w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Doxorubicin+Gemcitabine</intervention_name>
    <description>Gemcitabine 1000mg/m2,d1,8,iv; Liposomal Doxorubicin 30mg/m2,d1,iv.q4w of each 28 day cycle. 6 of Cycles: until progression or unacceptable toxicity develops or Progressive Disease.</description>
    <arm_group_label>Liposomal Doxorubicin+Gemcitabine</arm_group_label>
    <other_name>Liposomal Doxorubicin plus Gemcitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX4</intervention_name>
    <description>Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.</description>
    <arm_group_label>FOLFOX4</arm_group_label>
    <other_name>Oxaliplatin plus Fluorouracil/Leucovorin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible patients were age 18 to 75 years;

          -  The patients had histologically, cytologically,or clinically diagnosed unresectable
             HCC;and were ineligible for local invasive treatment. Clinically diagnosed patients
             had to have: (1) evidence of HBV or HCV with hepatic cirrhosis; (2) a-fetoprotein
             levels 400g/L; and (3) morphologic evidence of hypervascular liver tumor. Patients had
             to have at least one measurable lesion according to RECIST (version 1.0; ≥2 cm on
             computed tomography [CT]; 1 cm on spiral CT or magnetic resonance imaging). Lesions
             that had undergone previous interventional or local therapy were not considered
             measurable lesions.

          -  ECOG score≤2;

          -  life expectancy 3 months;

          -  Barcelona Clinic liver cancer (BCLC) stage B or C disease;

          -  Child-Pugh stage A or B disease;

          -  Adequate organ and marrow function, with neutrophil count≥1.5X10e9/L, platelet
             count≥75×10e9/L, AST or ALT﹤2.5×upper limit of normal (ULN), total bilirubin ＜1.5×ULN,
             international normalized ratio ＜1.5;normal baseline left ventricular ejection
             fraction_lower limit of normal for the institution. Patients with AST and ALT＜ 5 ×ULN
             could be recruited if total bilirubin was in the normal range.

          -  Patients had to provide signed informed consent to participate.

        Exclusion Criteria:

          -  documented allergy to platinum compounds or other study drugs; any previous OXA or DOX
             treatment, except adjuvant treatment ﹥12 months before random assignment;

          -  Previous liver transplantation;

          -  concomitant use of any other anticancer therapy, including interferon alfa and herbal
             medicine approved by the local authority to be used as anticancer medicine (except
             palliative radiotherapy to a nontarget lesion);

          -  CNS metastasis;

          -  Other serious illness or medical condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>lequn Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>GXMU</affiliation>
  </overall_official>
  <results_reference>
    <citation>Lombardi G, Zustovich F, Farinati F, Cillo U, Vitale A, Zanus G, Donach M, Farina M, Zovato S, Pastorelli D. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Cancer. 2011 Jan 1;117(1):125-33. doi: 10.1002/cncr.25578. Epub 2010 Aug 31.</citation>
    <PMID>21058409</PMID>
  </results_reference>
  <results_reference>
    <citation>Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643. Epub 2013 Aug 26.</citation>
    <PMID>23980077</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>March 17, 2016</last_update_submitted>
  <last_update_submitted_qc>March 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Chengcheng Liao</investigator_full_name>
    <investigator_title>Affiliated Tumor Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

